In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on Inotiv (NOTV – Research Report), with a price target of $10.00. The company’s shares closed yesterday at $1.76.
Takkinen covers the Healthcare sector, focusing on stocks such as NeuroPace, Apyx Medical, and Iradimed. According to TipRanks, Takkinen has an average return of -13.4% and a 29.03% success rate on recommended stocks.
Inotiv has an analyst consensus of Moderate Buy, with a price target consensus of $10.00.
See Insiders’ Hot Stocks on TipRanks >>
Based on Inotiv’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $101.17 million and a net profit of $1.84 million. In comparison, last year the company earned a revenue of $172.67 million and had a GAAP net loss of $3.73 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inotiv (NOTV) Company Description:
Bioanalytical Systems, Inc. operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The firm operates through the following business segments: Contract Research Services and Research Products. The Contract Research Services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing. The Research Products segment designs, develops, manufactures, and markets vivo sampling systems and accessories, physiology monitoring tools, liquid chromatography, and electrochemistry instruments platforms. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.
Read More on NOTV:
